HLS Therapeutics (TSE:HLS) Given New C$3.25 Price Target at Stifel Nicolaus

HLS Therapeutics (TSE:HLS) had its price objective dropped by investment analysts at Stifel Nicolaus from C$3.75 to C$3.25 in a research report issued to clients and investors on Tuesday, BayStreet.CA reports. Stifel Nicolaus’ price objective points to a potential upside of 4.84% from the stock’s previous close.

Separately, Raymond James cut their price objective on HLS Therapeutics from C$5.00 to C$4.00 in a research note on Friday, May 10th.

HLS Therapeutics Price Performance

TSE:HLS traded down C$0.13 during trading hours on Tuesday, hitting C$3.10. The company’s stock had a trading volume of 773,600 shares, compared to its average volume of 28,437. The stock has a fifty day simple moving average of C$3.39 and a 200-day simple moving average of C$3.94. The company has a market capitalization of C$98.61 million, a P/E ratio of -2.61 and a beta of 1.05. The company has a debt-to-equity ratio of 95.54, a current ratio of 1.56 and a quick ratio of 1.01. HLS Therapeutics has a twelve month low of C$3.01 and a twelve month high of C$5.52.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.